Cuba has registered in Peru what it claims is the world’s first lung cancer vaccine and is registering it in other South American countries.
The vaccine, called CIMAVAX-EGF, was first registered in 2008 in Cuba, where it was developed 15 years ago. More than a thousand Cuban patients were successfully treated by the vaccine, according to Gisela González, medical researcher from the Immunologic Molecular Center (CIM) in Havana.
Gonzalez describes CIMAVAX-EGF as derived from a protein produced by lung cancer. She said it is safe because patients who received the vaccine felt no side effects.
The vaccine prolongs a patient’s life after chemotherapy or radiotherapy by preventing cancer from returning.
Aside from registering the vaccine in Colombia, Brazil, Paraguay, Ecuador, and Argentina, it will undergo experimental trial in China, said Gonzalez. She added that CIMAVAX-EGF is being tested in treating breast, prostate and uterus cancer.
Last year, researchers at New York Presbyterian-Weill Cornell Medical Center were reported to have discovered a similar vaccine that is being tested on lung cancer patients worldwide.
The Ig Nobels are a highlight of the scientific calendar and award research that makes people laugh as well as think. The awards were presented last week at Harvard University in the U.S, and winning research included a bra that doubles as two face masks, a process for making diamonds from tequila, and Zimbabwe’s scheme to simplify the handling of money. The Ig Nobels began in 1991 and are awarded each October from Oslo and Stockholm. The awards are presented at a ceremony at Harvard, run by the university magazine Annals of Improbable Research. The Ig Nobels are awarded in categories such as Biology, Chemistry, Economics, Literature, Mathematics, Medicine, Peace, Physics, Continue reading →